Annual report pursuant to Section 13 and 15(d)

Summary of significant accounting policies (Tables)

v3.3.0.814
Summary of significant accounting policies (Tables)
12 Months Ended
Jul. 31, 2015
Accounting Policies [Abstract]  
Schedule Of Segment Revenue And Revenue Percentage [Table Text Block] The following table summarizes the Clinical Lab segment’s net revenues and revenue percentages by revenue category:

    Years Ended July 31,
    2015     2014     2013  
Revenue category   Amount     %     Amount     %     Amount     %  
Third-party payers   $ 35,631       56     $   29,509       50     $   26,014       47  
Medicare     11,981       19       12,815       22       12,497       22  
Patient self-pay     11,028       17       11,204       19       12,172       22  
HMO’s     4,774       8       5,161       9       5,206       9  
Total   $ 63,414       100 %   $ 58,689       100 %   $ 55,889       100 %
Schedule Of Accounts Receivable By Segment [Table Text Block] The following is a table of the Company’s net accounts receivable by segment.

    July 31, 2015     July 31, 2014  
Net accounts receivable by segment   Amount     %     Amount     %  
Clinical Labs (by billing category)                                
Third party payers   $ 3,595       44     $ 3,499       46  
Patient self-pay     3,213       39       2,193       29  
Medicare     1,081       13       1,558       21  
HMO’s     305       4       280       4  
Total Clinical Labs     8,194       100 %     7,530       100 %
                                 
Total Life Sciences     3,915               4,940          
Total accounts receivable – net   $ 12,109             $ 12,470          
Schedule of Allowance for Doubtful Accounts Receivable [Table Text Block] Changes in the Company’s allowance for doubtful accounts are as follows:

    July 31, 2015     July 31, 2014  
Beginning balance   $ 2,142     $ 2,707  
Provision for doubtful accounts     2,284       3,063  
Write-offs     (2,640 )     (3,628 )
Ending balance   $ 1,786     $ 2,142  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] The following table sets forth the computation of basic and diluted net loss per share for the years ended July 31:

    2015     2014     2013  
Net loss   $ (2,285 )   $ (9,977 )   $ (18,237 )
                         
Weighted-average common shares outstanding - basic     45,355       42,561       39,607  
Add: effect of dilutive stock options and restricted stock                  
Weighted-average common shares outstanding - diluted     45,355       42,561       39,607  
                         
Net income (loss) per share – basic and diluted   $ (0.05 )   $ (0.23 )   $ (0.46 )
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statement of operations for the years ended July 31:

    2015     2014     2013  
Cost of clinical laboratory services   $ 5     $ 9     $ 10  
Research and development     2       1       2  
Selling, general and administrative     422       584       533  
    $ 429     $ 594     $ 545